What is the role of recombinant factor VIIa in the treatment of hereditary and acquired hypercoagulability?

Updated: Jan 05, 2018
  • Author: Paul Schick, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

Recombinant factor VIIa has been proposed as a reversal agent for patients who bleed while undergoing anticoagulation. However, as yet there have been no controlled studies to determine its efficacy. Thrombosis may be a significant risk of recombinant factor VIIa therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!